Eli Lilly and Company (NYSE:LLY – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and target prices for Eli Lilly and Company and Nutriband, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eli Lilly and Company | 1 | 3 | 25 | 1 | 2.87 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Eli Lilly and Company presently has a consensus target price of $1,311.96, indicating a potential upside of 10.73%. Given Eli Lilly and Company’s stronger consensus rating and higher possible upside, equities analysts plainly believe Eli Lilly and Company is more favorable than Nutriband.
Risk & Volatility
Earnings & Valuation
This table compares Eli Lilly and Company and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eli Lilly and Company | $65.18 billion | 17.11 | $20.64 billion | $29.80 | 39.76 |
| Nutriband | $2.04 million | 49.18 | -$8.23 million | ($0.53) | -15.57 |
Eli Lilly and Company has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Eli Lilly and Company and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eli Lilly and Company | 33.53% | 97.83% | 23.23% |
| Nutriband | -430.35% | -109.07% | -95.54% |
Summary
Eli Lilly and Company beats Nutriband on 12 of the 15 factors compared between the two stocks.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
